NRx Pharmaceuticals, Inc (NRXP) - רווחיות מכירות גולמית

סמלים רשמיים של חברת NRx Pharmaceuticals Inc. (NRXP)

Liquidity shortages and asset restructuring create serious challenges for NRx Pharmaceuticals (NRXP). The estimated gross margin, reacting to Fed policy, is fixed at 25.20, signaling risks in the event of a trend reversal. The firm's stability is based on the development of therapies for severe psychiatric conditions, and the business's success depends on regulatory approval of the drug NRX-101.

NRXP (NRx Pharmaceuticals, Inc) היסטוריית רווחיות גולמית מ-04.07.2022 עד 20.11.2026

פילוחי מדדים פיננסיים ומדדי שוק עבור NRx Pharmaceuticals, Inc (NRXP)

- מחיר מניה ומחיר יעד קונצנזוס:
ניתוח בסיסי של החברה:NRx Pharmaceuticals Inc. (NRXP)
מוצרים מיוצרים של NRx Pharma

Gross margin measures production efficiency by capturing the portion of revenue remaining after deducting direct product creation costs. By analyzing the gross margin history, an investor assesses the ability of NRx Pharmaceuticals (NRXP) to balance drug synthesis automation against the high costs of recruiting psychiatrists for clinical trials, which directly determines the stability of the company's operating profit.